The GABAA-BZR complex as target for the development of anxiolytic drugs

Current Topics in Medicinal Chemistry

Volumn 12, Issue 4, 2012, Pages 254-269

  Trincavelli, Maria Letizia ^a   da Pozzo, Eleonora ^a   Daniele, Simona ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anxiety disorders; Anxiolytic drugs; Benzodiazepine binding site; GABAA receptor; GABAA receptor subunits

Indexed keywords

3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ABECARNIL; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR; BRETAZENIL; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIAZEPAM; EARLY GROWTH RESPONSE FACTOR 1; FLUMAZENIL; FLURAZEPAM; GLYCINE RECEPTOR; HYPNOTIC AGENT; MUSCLE RELAXANT AGENT; OCINAPLON; OLIGOMER; PAGOCLONE; SEROTONIN 3 AGONIST; VASOPRESSIN; ZALEPLON; ZOLPIDEM;

ALLOSTERISM; ALPHA CHAIN; AMYGDALOID NUCLEUS; ANXIETY DISORDER; BETA CHAIN; BINDING AFFINITY; BINDING SITE; COGNITIVE DEFECT; CONFORMATIONAL TRANSITION; DRUG EFFICACY; ELECTROPHYSIOLOGY; GENE PRODUCT; GENETIC ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MUSCLE RELAXATION; NEGATIVE FEEDBACK; NEUROSIS; NONHUMAN; REVIEW; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY DISORDERS; BENZODIAZEPINES; BINDING SITES; BRAIN; GABA-A RECEPTOR AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPNOTICS AND SEDATIVES; PROTEIN BINDING; PROTEIN SUBUNITS; RECEPTORS, GABA-A; TRANQUILIZING AGENTS;

EID: 84856472656     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026799078787     Document Type: Review

References (185)

1. Gordon, J.A.; Hen, R. Genetic approaches to the study of anxiety. Annu. Rev. Neurosci., 2004, 27, 193-222.
2. Herry, C.; Ferraguti, F.; Singewald, N.; Letzkus, J.J.; Ehrlich, I.; Lüthi, A. Neuronal circuits of fear extinction. Eur. J. Neurosci., 2010, 31,599-612.
3. Maren, S. Pavlovian fear conditioning as a behavioral assay for hippocampus and amygdala function: cautions and caveats. Eur. J. Neurosci., 2008, 28, 1661-1666.
4. Quirk, G.J.; Mueller, D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacol., 2008, 33, 56-72.
5. Shin, L.M.; Liberzon, I. The Neurocircuitry of Fear, Stress, and Anxiety Disorders Neuropsychopharmacol. Rev., 2010, 35, 169-191.
6. Pape, H.C.; Pare, D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev., 2010, 90, 419-463.
7. Gross, C.; Hen, R. The developmental origins of anxiety. Nat. Rev. Neurosci., 2004, 5, 545-552.
8. Davis, M. The role of the amygdala in fear and anxiety. Annu. Rev. Neurosci., 1992, 15, 353-375.
9. Wallace, K.J.; Rosen, J.B. Neurotoxic lesions of the lateral nucleus of the amygdala decrease conditioned fear but not unconditioned fear of a predator odor: comparison with electrolytic lesions. J. Neurosci., 2001, 21, 3619-3627.
10. Blair, H.T.; Sotres-Bayon, F.; Moita, M.A.; Ledoux J.E. The lateral amygdala processes the value of conditioned and unconditioned aversive stimuli. Neurosci., 2005, 133, 561-569.
11. Goosens, K.A.; Maren, S. Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learn. Mem., 2001, 8, 148-155.
12. Anglada-Figueroa, D.; Quirk, G.J. Lesions of the basal amygdale block expression of conditioned fear but not extinction. J. Neurosci., 2005, 25, 9680-9685.
13. Le Doux, J.E. Emotion circuits in the brain. Annu. Rev. Neurosci., 2000, 23, 155-184.
14. Sotres-Bayon, F.; Cain, C.K.; LeDoux, J.E. Brain mechanisms of fear extinction: historical perspectives on the contribution of prefrontal cortex. Biol. Psychiatry, 2006, 60, 329-336.
15. Davis, M.; Rainnie, D.; Cassell, M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci., 1994, 17, 208-214.
16. Selye, H. The evolution of the stress concept. Am. Sci., 1973, 61, 692-699.
17. Smith, S.M.; Vale, W.W. The role of the hypothalamic-pituitaryadrenal axis in neuroendocrine responses to stress. Dialogues Clin. Neurosci., 2006, 8, 383-395.
18. Vermetten, E.; Bremner, J.D. Circuits and systems in stress. II. Applications to neurobiology and treatment in posttraumatic stress disorder. Depress. Anxiety, 2002, 16, 14-38.
19. Whiting, P.J. GABA-A receptors: a viable target for novel anxiolytics? Curr. Opin. Pharmacol., 2006, 6, 24-29.
20. Lydiard, R.B. The role of GABA in anxiety disorders. J. Clin. Psychiatry. 2003, 64, 21-27.
21. Kent, J.M.; Mathew, S.J.; Gorman, J.M. Molecular targets in the treatment of anxiety. Biol. Psychiatry, 2002, 52, 1008-1030.
22. Nutt, D.J.; Malizia, A.L. New insights into the role of the GABAAbenzodiazepine receptor in psychiatric disorder. Br. J. Psychiatry, 2001, 179, 390-396.
23. Malizia, A.L.; Cunningham, V.J.; Bell, C.J.; Liddle, P.F.; Jones, T.; Nutt, D.J. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry, 1998, 55, 715-720.
24. Nikolaus, S.; Antke, C.; Beu, M.; Müller, H.W. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders--results from in vivo imaging studies. Rev. Neurosci., 2010, 21, 119-139.
25. Tiihonen, J.; Kuikka, J.; Räsänen, P.; Lepola, U.; Koponen, H.; Liuska, A.; Lehmusvaara, A.; Vainio, P.; Könönen, M.; Bergström, K.; Yu, M.; Kinnunen, I.; Akerman, K.; Karhu, J. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol. Psychiatry, 1997, 2, 463-471.
26. Bremner, J.D.; Innis, R.B.; Southwick, S.M.; Staib, L.; Zoghbi, S.; Charney, D.S. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am. J. Psychiatry, 2000, 157, 1120-1126.
27. Bielau, H.; Steiner, J.; Mawrin, C.; Trübner, K.; Brisch, R.; Meyer- Lotz, G.; Brodhun, M.; Dobrowolny, H.; Baumann, B.; Gos, T.; Bernstein, H.G.; Bogerts, B. Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann. N Y Acad. Sci. USA, 2007, 1096, 157-169.
28. Schlösser, R.G.; Gesierich, T.; Wagner, G.; Bolz, M.; Gründer, G.; Dielentheis, T.F.; Scherb, C.; Stoeter, P. Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge. Psychiatry Res., 2007, 154, 241-251.
29. Hasler, G.; van der Veen, J.W.; Tumonis, T.; Meyers, N.; Shen, J.; Drevets, W.C. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry, 2007, 64, 193-200.
30. Newell, K.A.; Zavitsanou, K.; Jew, S.K.; Huang, X.F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 225-233.
31. Scanziani, M. GABA spillover activates postsynaptic GABAB receptors to control rhythmic hippocampal activity. Neuron, 2000, 25, 673-681.
32. Semyanov, A.; Walker, M.C.; Kullmann, D.M.; Silver, R.A. Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci., 2004, 27, 262-269.
33. Farrant, M.; Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci., 2005, 6, 215-229.
34. De Groote, L.; Linthorst, A.C.E. Exposure to novelty and forced swimming evoke stressor-dependent changes in extracellular GABA in the rat hippocampus. Neurosci., 2007, 148, 794-805.
35. Ham, B.J.; Sung, Y.; Kim, N.; Kim, S.J.; Kim, J.E.; Kim, D.J.; Lee, J.Y.; Kim, J.H.; Yoon, S.J.; Lyoo, I.K. Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1HMRS) study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 403-411.
36. Hasler, G.; van der Veen, J.W.; Grillon, C.; Drevets, W.C.; Shen, J. Effect of acute psychological stress on prefrontal GABA concentration determined by proton magnetic resonance spectroscopy. Am. J. Psychiatry, 2010, 167, 1226-1231.
37. Jacob, T.C.; Moss, S.J.; Jurd, R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat. Rev. Neurosci., 2008, 9, 331-343.
38. Macdonald, R.L.; Olsen, R.W. GABAA receptor channels. Annu. Rev. Neurosci., 1994, 17, 569-602.
39. Sieghart, W. Structure and pharmacology of GABAA receptor subtypes. Pharmacol. Rev., 1995, 47, 181-234.
40. Mody, I.; Pearce, R.A. Diversity of inhibitory neurotransmission through GABAA receptors. Trends Neurosci., 2004, 27, 569-575.
41. Martin, D.L.; Olsen, R.W. GABA in the Nervous System: The View at 50 Years. Lippincott, Williams & Wilkins, New York, 2000.
42. Buckingham, S.D.; Biggin, P.C.; Sattelle, B.M.; Brown, L.A.; Sattelle, D.B. Insect GABA receptors: splicing, editing, and targeting by antiparasitics and insecticides. Mol. Pharmacol., 2005, 68, 942-951.
43. Bailey, S.J.; Ravier, M.A.; Rutter, G.A. Glucose-dependent regulation of gamma-aminobutyric acid (GABA A) receptor expression in mouse pancreatic islet alpha-cells. Diabetes, 2007, 56, 320-327.
44. Corringer, P.J.; Le Novere, N.; Changeux, J.P. Nicotinic receptors at the amino acid level. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 431-458.
45. Lukas, R.J.; Bencherif, M. Recent developments in nicotinic acetylcholine receptor biology. In Biological and Biophysical Aspects of Ligand-gated Ion Channel Receptor Superfamilies; Arias, H. R.; Eds.; Research Signpost, Kerala, India, 2006; pp 2-33.
46. Breitinger, H.G.; Becker, C.M. The inhibitory glycine receptor simple views of a complicated channel. ChemBioChem, 2002, 3, 1042-1052.
47. Davies, P.A.; Pistis, M.; Hanna, M.C.; Peters, J.A.; Lambert, J.J.; Hales, T.G.; Kirkness, E.F. The 5-HT3B subunit is a major determinant of serotonin receptor function. Nature, 1999, 397, 359-363.
48. Thompson, A.J.; Lummis, S.C.R. 5-HT3 receptors. Curr. Pharm. Des., 2006, 12, 3615-3630.
49. 2+. J. Biol. Chem., 2003, 278, 712-717.
50. Sine, S.; Engel, A. Recent advances in Cys-loop receptor structure and function. Nature, 2006, 440, 448-455.
51. Peters, J.A.; Hales, T.G.; Lambert, J.J. Molecular determinants of single channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT3 receptor. Trends Pharmacol. Sci., 2005, 26, 587-594.
52. Brejc, K.; van Dijk, W.J.; Klaassen, R.V.; Schuurmans, M.; van Der Oost, J.; Smit, A.B.; Sixma, T.K. Crystal structure of an AChbinding protein reveals the ligand binding domain of nicotinic receptors. Nature, 2001, 411, 269-276.
53. Dellisanti, C.H.; Yao, Y.; Stroud, J.C.; Wang, Z.Z.; Chen, L. Crystal structure of the extracellular domain of nAChR a1 bound to abungarotoxin at 1.94 A resolution. Nat. Neurosci., 2007, 10, 953-962.
54. Hemmings, Jr. H.C.; Akabas, M.H.; Goldstein, P.A.; Trudell, J.R.; Orser, B.A.; Harrison, N.L. Emerging molecular mechanisms of general anestheticaction. Trends Pharmacol. Sci., 2005, 26, 503-510.
55. Mitchell, E.A.; Herd, M.B.; Gunn, B.G.; Lambert, J.J.; Belelli, D. Neurosteroid modulation of GABAA receptors: molecular determinants and significance in health and disease. Neurochem. Int., 2008, 52, 588-595.
56. Sigel, E. Mapping of the benzodiazepine recognition site on GABAA receptors. Curr. Top. Med. Chem., 2002, 2, 833-839.
57. Simon, J.; Wakimoto, H.; Fujita, N.; Lalande, M.; Barnard, E.A. Analysis of the set of GABAA receptor genes in the human genome. J. Biol. Chem., 2004, 279, 41422-41435.
58. Barnard, E.A.; Skolnick, P.; Olsen, R.W.; Mohler, H.; Sieghart, W.; Biggio, G.; Braestrup, C.; Bateson, A.N.; Langer, S.Z. Subtypes of g- aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev., 1998, 50, 291-313.
59. Olsen, R.W.; Sieghart, W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacol., 2009, 56, 141-148.
60. D'Hulst, C.; Atack, J.R.; Kooy, R.F. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov. Today, 2009, 14, 866-875.
61. Olsen, R.W.; Sawyer, G.W. GABAA receptor. In: Encyclopedia of Biological Chemistry, Elsevier, New York, 2004, pp 162-166.
62. Wisden, W.; Laurie, D.J.; Monyer, H.; Seeburg, P.H. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci., 1992, 12, 1040-1062.
63. Laurie, D.J.; Wisden, W.; Seeburg, P.H. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J. Neurosci., 1992, 12, 4151-4172.
64. Persohn, E.; Malherbe, P.; Richards, J.G. Comparative molecular neuroanatomy of cloned GABAA receptor subunits in the rat CNS. J. Comp. Neurol., 1992, 326, 193-216.
65. Fritschy, J.M.; Mohler, H. GABAA receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol., 1995, 359, 154-194.
66. Pirker, S.; Schwarzer, C.; Wieselthaler, A.; Sieghart, W.; Sperk, G. GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neurosci., 2000, 101, 815-833.
67. Whiting, P.J.; Wafford, K.A.; McKernan, R.M. Pharmacological subtypes of GABAA receptors based on subunit composition. In GABA in the Nervous System: The View at Fifty Years. Martin, D. L.; Olsen, R. W.; Eds.; Lippincott Williams & Wilkins, Philadelphia, 2000, pp. 113-126.
68. Sieghart, W.; Ernst, M. Heterogeneity of GABAA receptors: revived interest in the development of subtype-selective drugs. Curr. Med. Chem. Cent. Nerv. Syst. Agents, 2005, 5, 217-242.
69. Sur, C.; Wafford, K.A.; Reynolds, D.S.; Hadingham, K.L.; Bromidge, F.; Macaulay, A.; Collinson, N.; O'Meara, G.; Howell, O.; Newman, R.; Myers, J.; Atack, J.R.; Dawson, G.R.; McKernan, R.M.; Whiting, P.J.; Rosahl, T.W. Loss of the major GABAA receptor subtype in the brain is not lethal in mice. Neurosci., 2001, 21, 3409-3418.
70. Zhang, J.H.; Sato, M.; Tohyama, M. Different postnatal development profiles of neurons containing distinct GABAA receptor bsubunit mRNAs (bα1, b 2, and b 3) in the rat forebrain. J. Comp. Neurol., 1991, 308, 586-613.
71. Klausberger, T.; Roberts, J.D.B.; Somogyi, P. Cell type and inputspecific differences in the number and subtypes of synaptic GABAA receptors in the hippocampus. J. Neurosci., 2002, 22, 2513-2521.
72. Jechlinger, M.; Pelz, R.; Tretter, V.; Klausberger, T.; Sieghart, W. Subunit composition and quantitative importance of heterooligomeric receptors: GABAA receptors containing a6 subunits. J. Neurosci., 1998, 18, 2449-2457.
73. Poltl, A.; Hauer, B.; Fuchs, K.; Tretter, V.; Sieghart, W. Subunit composition and quantitative importance of GABAA receptor subtypes in the cerebellum of mouse and rat. J. Neurochem., 2003, 87, 1444-1455.
74. Benke, D.; Mertens, S.; Trzeciak, A.; Gillessen, D.; Mohler, H. GABAA receptors display association of gamma2 subunits with alpha1 and alpha2/3 subunits. J. Biol. Chem., 1991, 266, 4478-4483.
75. Somogyi, P.; Fritschy, J.M.; Benke, D.; Roberts, J.D.; Sieghart, W. The gamma 2 subunit of the GABAA receptor is concentrated in synaptic junctions containing the alpha 1 and beta 2/3 subunits in hippocampus, cerebellum and globus pallidus. Neuropharmacol., 1996, 35, 1425-1444.
76. Barrera, N.P.; Betts, J.; You, H.; Henderson, R.M.; Martin, I.L.; Dunn, S.M.J.; Edwardson, J.M. Atomic force microscopy reveals the stoichiometry and subunit arrangement of the α4 β3γ GABAA receptor. Mol. Pharmacol., 2008, 73, 960-967.
77. Olsen, R.W. Extrasynaptic GABAA receptors in the nucleus accumbens are necessary for alcohol drinking. Proc. Natl. Acad. Sci. USA, 2011, 108, 4699-4700.
78. Nusser, Z.; Sieghart, W.; Somogyi, P. Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells. J. Neurosci., 1998, 18, 1693-1703.
79. Wei, W.; Zhang, N.; Peng, Z.; Houser, C.R.; Mody, I. Perisynaptic localization of a subunit containing GABAA receptors and their activation by GABA spillover in the mouse dentate gyrus. J. Neurosci., 2003, 23, 10650-10661.
80. Korpi, E.R.; Grunder, G.; Luddens, H. Drug interactions at GABAA receptors. Prog. Neurobiol., 2002, 67, 113-159.
81. Sperk, G.; Schwarzer, C.; Tsunashima, K.; Fuchs, K.; Sieghart, W. GABAA receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits. Neuroscience, 1997, 80, 987-1000.
82. Hadingham, K.L.; Wingrove, P.B.; Wafford, K.A.; Bain, C.; Kemp, J.A.; Palmer, K.J.; Wilson, A.W.; Wilcox, A.S.; Sikela, J.M.; Ragan, C.I.; Whiting, P.J. Role of the beta subunit in determining the pharmacology of human gamma-aminobutyric acid type A receptors. Mol. Pharmacol., 1993, 44, 1211-1218.
83. Pritchett, D.B.; Sontheimer, H.; Shivers, B.D.; Ymer, S.; Kettenmann, H.; Schofield, P.R.; Seeburg, P.H. Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature, 1989, 338, 582-585.
84. Khom, S.; Baburin, I.; Timin, E.N.; Hohaus, A.; Sieghart, W.; Hering, S. Pharmacological properties of GABAA receptors containing g1 subunits. Mol. Pharmacol., 2006, 69, 640-649.
85. Sieghart, W. Multiplicity of GABAA benzodiazepine receptors. Trends Pharmacol. Sci., 1989, 10, 407-411.
86. Olsen, R.W.; Gordey, M. GABAA receptor chloride ion channels. In Handbook of Experimental Pharmacology, Pharmacology of Ionic Channel Function: Activators and Inhibitors. Endo, M.; Kurachi, Y.; Mishina, M.; Eds.; Springer Verlag, Heidelberg, 2000, pp 499-517.
87. Depoortere, H.; Zivkovic, B.; Lloyd, K.G.; Sanger, D.J.; Perrault, G.; Langer, S.Z.; Bartholini, G. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther., 1986, 237, 649-658.
88. Smith, A.J.; Alder, L.; Silk, J.; Adkins, C.; Fletcher, A.E.; Scales, T.; Kerby, J.; Marshall, G.; Wafford, K.A.; McKernan, R.M.; Atack, J.R. Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gammaaminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol. Pharmacol., 2001, 59, 1108-1118.
89. Amin, J.; Brooks-Kayal, A.; Weiss, D.S. Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of α-aminobutyric acidA receptors. Mol. Pharmacol., 1997, 51, 833-841.
90. Buhr, A.; Schaerer, M.T.; Baur, R.; Sigel, E. Residues at positions 206 and 209 of the α1 subunit of α-aminobutyric AcidA receptors influence affinities for benzodiazepine binding site ligands. Mol. Pharmacol., 1997, 52, 676-682.
91. Wieland, H.A.; Luddens, H.; Seeburg, P.H. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J. Biol. Chem., 1992, 267, 1426-1429.
92. Liu, R.; Hu, R.J.; Zhang, P.; Skolnick, P.; Cook, J.M. Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors. J. Med. Chem., 1996, 39, 1928-1934.
93. Quirk, K.; Blurton, P.; Fletcher, S.; Leeson, P.; Tang, F.; Mellilo, D.; Ragan, C.I.; McKernan, R.M. [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit. Neuropharmacol., 1996, 35, 1331-1335.
94. Skolnick, P.; Hu, R.J.; Cook, C.M.; Hurt, S.D.; Trometer, J.D.; Liu, R.; Huang, Q.; Cook, J.M. [3H]RY 80: A high-affinity, selective ligand for α-aminobutyric acidA receptors containing alpha-5 subunits. J. Pharmacol. Exp. Ther., 1997, 283, 488-493.
95. Rudolph, U.; Crestani, F.; Benke, D.; Brunig, I.; Benson, J.A.; Fritschy, J.M.; Martin, J.R.; Bluethmann, H.; Mohler, H. Benzodiazepine actions mediated by specific α-aminobutyric acidA receptor subtypes. Nature, 1999, 401, 796-800.
96. McKernan, R.M.; Rosahl, T.W.; Reynolds, D.S.; Sur, C.; Wafford, K.A.; Atack, J.R.; Farrar, S.; Myers, J.; Cook, G.; Ferris, P.; Garrett, L.; Bristow, L.; Marshall, G.; Macaulay, A.; Brown, N.; Howell, O.; Moore, K.W.; Carling, R.W.; Street, L.J.; Castro, J.L.; Ragan, C.I.; Dawson, G.R.; Whiting, P.J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. Nat. Neurosci., 2000, 3, 587-592.
97. Heldt, S.A.; Ressler, K.J. Amygdala-specific reduction of α1- GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice. J. Neurosci., 2010, 21, 7139-7151.
98. Low, K.; Crestani, F.; Keist, R.; Benke, D.; Brunig, I.; Benson, J.A., Fritschy, J.M.; Rulicke, T.; Bluethmann, H.; Mohler, H.; Rudolph, U. Molecular and Neuronal Substrate for the Selective Attenuation of Anxiety. Science, 2000, 290,131-134.
99. Crestani, F.; Low, K.; Keist, R.; Mandelli, M.; Mohler, H.; Rudolph, U. Molecular Targets for the Myorelaxant Action of Diazepam. Mol. Pharmacol., 2001, 59, 442-445.
100. Crestani, F.; Keist, R.; Fritschy, J.M.; Benke, D.; Vogt, K.; Prut, L.; Blüthmann, H.; Möhler, H.; Rudolph, U. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc. Natl. Acad. Sci. USA, 2002, 99, 8980-8985.
101. Chambers, M.S.; Atack, J.R.; Carling, R.W.; Collinson, N.; Cook, S.M.; Dawson, G.R.; Ferris, P.; Hobbs, S.C.; O'connor, D.; Marshall, G.; Rycroft, W.; Macleod, A.M. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA α5 receptors with cognition enhancing properties. J. Med. Chem., 2004, 47, 5829-5832.
102. Sternfeld, F.; Carling, R.W.; Jelley, R.A.; Ladduwahetty, T.; Merchant, K.J.; Moore, K.W.; Reeve, A.J.; Street, L.J.; O'Connor, D.; Sohal, B.; Atack, J.R.; Cook, S.; Seabrook, G.; Wafford, K.; Tattersall, F.D.; Collinson, N.; Dawson, G.R.; Castro, J.L.; MacLeod, A.M. Selective, orally active γ-aminobutyric acida α5 receptor inverse agonists as cognition enhancers. J. Med. Chem., 2004, 47, 2176-2179.
103. Street, L.J.; Sternfeld, F.; Jelley, R.A.; Reeve, A.J.; Carling, R.W.; Moore, K.W.; McKernan, R.M.; Sohal, B.; Cook, S.; Pike, A.; Dawson, G.R.; Bromidge, F.A.; Wafford, K.A.; Seabrook, G.R.; Thompson, S.A.; Marshall, G.; Pillai, G.V.; Castro, J.L.; Atack, J.R.; MacLeod, A.M. Synthesis and biological evaluation of 3- heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4- a]phthalazines and analogues as subtype-selective inverse agonists for the GABAA α5 benzodiazepine binding site. J. Med. Chem., 2004, 47, 3642-3657.
104. Berezhnoy, Y.; Nyfeler, Y.; Gonthier, A.; Schwob, H.; Goeldner, M.; Sigel, E. On the benzodiazepine binding pocket in GABAA receptors. J. Biol. Chem., 2004, 279, 3160-3168.
105. McKernan, R.M.; Farrar, S.; Collins, I.; Emms, F.; Asuni, A.; Quirk, K.; Broughton, H. Photoaffinity labeling of the benzodiazepine binding site of α1β3γ2 γ-Aminobutyric AcidA GABAA receptors with flunitrazepam identifies a subset of ligands that interact directly with His102 of the α subunit and predicts orientation of these within the benzodiazepine pharmacophore. Mol. Pharmacol., 1998, 54, 33-43.
106. Tan, K.R.; Baur, R.; Gonthier, A.; Goeldner, M.; Sigel, E. Two neighboring residues of loop A of the α1 subunit point towards the benzodiazepine binding site of GABAA receptors. FEBS Lett., 2007, 581, 4718-4722.
107. Buhr, A.; Sigel, E. A point mutation in the γ2 subunit of γ- aminobutyric acid type A receptors results in altered benzodiazepine binding site specificity. Proc. Natl. Acad. Sci. USA, 1997, 94, 8824-8829.
108. Buhr, A.; Baur, R.; Sigel, E. Subtle changes in residue 77 of the γ subunit of α1α2β2 GABAA receptors drastically alter the affinity for ligands of the benzodiazepine binding site. J. Biol. Chem., 1997, 272, 11799-11804.
109. Kucken, A.M.; Wagner, D.A.; Ward, P.R.; Teissere, J.A.; Boileau, A.J.; Czajkowski, C. Identification of benzodiazepine binding site residues in the α2 subunit of the GABAA receptor. Mol. Pharmacol., 2000, 57, 932-939.
110. Teissere, J.A.; Czajkowski, C. A α-strand in the β2 subunit lines the benzodiazepine binding site of the GABAA receptor: structural rearrangements detected during channel gating. J. Neurosci., 2001, 21, 4977-4986.
111. Hanson, S.M.; Czajkowski, C. Structural mechanisms underlying benzodiazepine modulation of the GABAA receptor. J. Neurosci., 2008, 28, 3490-3499.
112. Padgett, C.L.; Lummis, S.C. The F-loop of the GABAA receptor α2 subunit contributes to benzodiazepine modulation. J. Biol. Chem., 2008, 283, 2702-2708.
113. Boileau, A.J.; Czajkowski, C. Identification of transduction elements for benzodiazepine modulation of the GABAA receptor: three residues are required for allosteric coupling. J. Neurosci, 1999, 19, 10213-10220.
114. Goldschen-Ohm, M.P.; Wagner, D.A.; Petrou, S.; Jones, M.V. An epilepsy related region in the GABAA receptor mediates longdistance effects on GABA and benzodiazepine binding sites. Mol. Pharmacol., 2010, 77, 35-45.
115. Lavoie, A.M.; Twyman, R.E. Direct evidence for diazepam modulation of GABAA receptor microscopic affinity. Neuropharmacol., 1996, 35, 1383-1392.
116. Mellor, J.R.; Randall, A.D. Frequency-dependent actions of benzodiazepines on GABAA receptors in cultured murine cerebellar granule cells. J. Physiol., 1997, 503, 353-369.
117. Thompson, S.A.; Smith, M.Z.; Wingrove, P.B.; Whiting, P.J.; Wafford, K.A. Mutation at the putative GABAA ion-channel gate reveals changes in allosteric modulation. Br. J. Pharmacol., 1999, 127, 1349-1358.
118. Campo-Soria, C.; Chang, Y.; Weiss, D.S. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol., 2006, 148, 984-990.
119. Downing, S.S.; Lee, Y.T.; Farb, D.H.; Gibbs, T.T. Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABAA receptors supports an allosteric model of modulation. Br. J. Pharmacol., 2005, 145, 894-906.
120. Rusch, D.; Forman, S.A. Classic benzodiazepines modulate the open-close equilibrium in α1β2γ2L γ-aminobutyric acid type A receptors. Anesthesiol., 2005, 102, 783-792.
121. Kloda, J.H.; Czajkowski, C. Agonist-, antagonist-, and benzodiazepine- induced structural changes in the α1 Met113-Leu132 region of the GABAA receptor. Mol. Pharmacol., 2007, 71, 483-493.
122. Sancar, F.; Czajkowski, C. Allosteric modulators induce distinct movements at the GABA-binding site interface of the GABA-A receptor. Neuropharmacol., 2011, 60, 520-528.
123. 11C]flumazenil PET imaging. Neuropharmacol., 2010, 59, 635-639.
124. Guerrini, G.; Ciciani, G.; Cambi, G.; Bruni, F.; Selleri, S.; Melani, F.; Montali, M.; Martini, C.; Ghelardini, C.; Norcini, M.; Costanzo, A. Novel 3-aroylpyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides 8- substituted, ligands at GABAA/benzodiazepine receptor complex: synthesis, pharmacological and molecular modeling studies. Bioorg. Med. Chem., 2008, 16, 4471-4489.
125. Iversen, L. GABA pharmacology-what prospects for the future? Biochem. Pharmacol., 2004, 68, 1537-1540.
126. Rowlett, J.K.; Platt, D.M.; Lelas, S.; Atack, J.R.; Dawson, G.R. Different GABAA receptor subtypes mediate the anxiolytic, abuserelated, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl. Acad. Sci. USA, 2005, 102, 915-920.
127. Atack, J.R.; Hutson, P.H.; Collinson, N.; Marshall, G.; Bentley, G.; Moyes, C.; Cook, S.M.; Collins, I.; Wafford, K.; McKernan, R.M.; Dawson, G.R. Anxiogenic properties of an inverse agonist selective for α3 subunit-containing GABAA Receptors. Br. J. Pharmacol., 2005, 144, 357-66.
128. Dias, R.; Sheppard, W.F.; Fradley, R.L.; Garrett, E.M.; Stanley, J.L.; Tye, S.J.; Goodacre, S.; Lincoln, R.J.; Cook, S.M.; Conley, R.; Hallett, D.; Humphries, A.C.; Thompson, S.A.; Wafford, K.A.; Street, L.J.; Castro, J.L.; Whiting, P.J.; Rosahl, T.W.; Atack, J.R.; McKernan, R.M.; Dawson, G.R.; Reynolds, D.S. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci., 2005, 25, 10682-10688.
129. Russell, M.G.; Carling, R.W.; Street, L.J.; Hallett, D.J.; Goodacre, S.; Mezzogori, E.; Reader, M.; Cook, S.M.; Bromidge, F.A.; Newman, R.; Smith, A.J.; Wafford, K.A.; Marshall, G.R.; Reynolds, D.S.; Dias, R.; Ferris, P.; Stanley, J.; Lincoln, R.; Tye, S.J.; Sheppard, W.F.A.; Sohal, B.; Pike, A.; Dominguez, M.; Atack, J.R.; Castro, J.L. Discovery of imidazo[1,2-b][1,2,4]triazines as GABAA_2/3 subtype selective agonists for the treatment of anxiety. J. Med. Chem., 2006, 49, 1235-1238.
130. Atack, J.R. GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. Curr. Top. Med. Chem., 2011, 11, 1176-1202.
131. Licata, S.C.; Platt, D.M.; Cook, J.M.; Sarma, P.V.; Griebel, G.; Rowlett, J.K. Contribution of GABAA receptor subtypes to the anxiolytic like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1- yl-carbonyl)-2,9- dihydro-1H-pyridol[3,4-b]indol-1-one]. J. Pharmacol. Exp. Ther., 2005, 313, 1118-1125.
132. Sandford, J.J.; Forshall, S.; Bell, C.; Argyropoulos, S.; Rich, A.; D'Orlando, K.J., Gammans, R.E.; Nutt, D.J. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J. Psychopharmacol., 2001, 15, 205-208.
133. Lingford-Hughes, A.; Wilson, S.J.; Feeney, A.; Grasby, P.G.; Nutt, D.J. A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist. Psychopharmacol., 2005, 180, 789-791.
134. Atack, J.R. GABAA receptor subtype-selective efficacy: TPA023, an α2/α3 selective non-sedating anxiolytic and α5IA, anα5 selective cognition enhancer. CNS Neurosci. Ther., 2008, 14, 25-35.
135. [Atack, J.R. Subtype-selective GABAA receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Adv. Pharmacol., 2009, 57, 137-185.
136. Petursson, H. The benzodiazepine withdrawal syndrome. Addiction, 1994, 89, 1455-1459.
137. Hutchinson, M.A.; Smith, P.F.; Darlington, C.L. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog. Neurobiol., 1996, 49, 73-97.
138. Licata, S.C.; Rowlett, J.K. Abuse and dependence liability of benzodiazepinetype drugs: GABAA receptor modulation and beyond. Pharmacol. Biochem. Behav., 2008, 90, 74-89.
139. Heikkinen, A.E.; Möykkynen, T.P.; Korpi, E.R. Long-lasting modulation of glutamatergic transmission in VTA dopamine neurons after a single dose of benzodiazepine agonists. Neuropsychopharmacol., 2009, 34, 290-298
140. Straub, C.J.; Carlezon, W.A.Jr.; Rudolph, U. Diazepam and cocaine potentiate brain stimulatioin reward in C57BL/6J mice. Behav. Brain. Res., 2010, 206, 17-20.
141. Vorma, H.; Naukkarinen, H.; Sarna, S.; Kuoppasalmi, K. Treatment of outpatients with complicated benzodiazepine dependence: camparison of two approaches. Addiction, 2002, 97, 851-859.
142. Vorma, H.; Naukkarinen, H.; Sarna, S.; Kuoppasalmi, K. Symptom severity and quality of life after benzodiazepine withdrawal treatment in particitipants with complicated dependence. Addict. Behav., 2004, 29, 1059-1065.
143. Rosenberg, H.C.; Chiu, T.H. Decreased 3H-diazepam binding is a specific response to chronic benzodiazepine treatment. Life. Sci., 1979, 24, 803-807.
144. Miller, L.G.; Roy, R.B.; Weill, C.L. Chronic clonazepam administration decreases gamma-aminobutyric acidA receptor function in cultured cortical neurons. Mol. Pharmacol., 1989, 36, 796-802.
145. Heninger, C.; Gallager, D.W. Altered gamma-aminobutyric acid/benzodiazepine interaction after chronic diazepam exposure. Neuropharmacol., 1988, 27, 1073-1076.
146. Ramsey-Williams, V.A.; Wu, Y.; Rosenberg, H.C. Comparison of anticonvulsant tolerance, crosstolerance, and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam. Pharmacol. Biochem. Behav., 1994, 48, 765-772.
147. Marley, R.J.; Gallager, D.W. Chronic diazepam treatment produces regionally specific changes in GABA-stimulated chloride influx. Eur. J. Pharmacol., 1989, 159, 217-223.
148. Tietz, E.I.; Chiu, T.H.; Rosenberg, H.C. Regional GABA/benzodiazepine receptor/chloride channel coupling after acute and chronic benzodiazepine treatment. Eur. J. Pharmacol., 1989, 167, 57-65.
149. Roca, D.J.; Schiller, G.D.; Friedman, L.; Rozenberg, I.; Gibbs, T.T.; Farb, D.H. Gamma-Aminobutyric acid A receptor regulation in culture: altered allosteric interactions following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines. Mol. Pharmacol., 1990, 37, 710-719.
150. Primus, R.J.; Gallager, D.W. GABAA receptor subunit mRNA levels are differentially influenced by chronic FG 7142 and diazepam exposure. Eur. J. Pharmacol., 1992, 226, 21-28.
151. Bateson, A.N. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr. Pharm. Des., 2002, 8, 5-21.
152. Impagnatiello, F.; Pesold, C.; Longone, P.; Caruncho, H.; Fritschy, J.M.; Costa, E.; Guidotti, A. Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. Mol. Pharmacol., 1996, 49, 822-831.
153. Longone, P.; Impagnatiello, F.; Guidotti, A.; Costa, E. Reversible modification of GABAA receptor subunit mRNA expression during tolerance to diazepaminduced cognition dysfunction. Neuropharmacol., 1996, 35, 1465-1473.
154. Pesold, C.; Caruncho, H.J.; Impagnatiello, F.; Berg, M.J.; Fritschy, J.M.; Guidotti, A.; Costa, E. Tolerance to diazepam and changes in GABAA receptor subunit expression in rat neocortical areas. Neurosci., 1997, 79, 477-487.
155. Johnston, J.D.; Bristow, D.R. Regulation of GABAA receptor α1 protein is a sensitive indicator of benzodiazepine agonist efficacy. Eur. J. Pharmacol., 1998, 348, 321-324.
156. Holt, R.A.; Martin, I.L.; Bateson, A.N. Chronic diazepam exposure decreases transcription of the rat GABAA receptor γ2-subunit gene. Mol. Brain. Res., 1997, 48, 164-166.
157. Holt, R.A.; Bateson, A.N.; Martin, I.L. Chronic zolpidem treatment alters GABAA receptor mRNA levels in the rat cortex. Eur. J. Pharmacol., 1997, 329, 129-132.
158. Holt, R.A.; Bateson, A.N.; Martin, I.L. Decreased GABA enhancement of benzodiazepine binding after a single dose of diazepam. J. Neurochem., 1999, 72, 2219-2222.
159. Kang, I.; Lindquist, D.G.; Kinane, T.B.; Ercolani, L.; Pritchard, G.A.; Miller, L.G. Isolation and characterization of the promoter of the human GABAA receptor α1 subunit gene. J. Neurochem., 1994, 62, 1643-1646.
160. Miranda, J.D.; Barnes, E.M.Jr. Repression of γ-aminobutyric acid type A receptor α1 polypeptide biosynthesis requires chronic agonist exposure. J. Biol. Chem., 1997, 272, 16288-16294.
161. Tehrani, M.H.; Barnes, E.M.Jr. Sequestration of γ-aminobutyric acidA receptors on clathrin-coated vesicles during chronic benzodiazepine administration in vivo. J. Pharmacol. Exp. Ther., 1997, 283, 384-390.
162. Low, K.; Crestani, F.; Keist, R.; Benke, D.; Brunig, I.; Benson, J.A.; Fritschy, J.M.; Rulicke, T.; Bluethmann, H.; Mohler, H.; Rudolph, U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science, 2000, 290, 131-134.
163. Edenberg, H.J.; Dick, D.M.; Xuei, X.; Tian, H.; Almasy, L.; Bauer, L.O.; Crowe, R.R.; Goate, A.; Hesselbrock, V.; Jones, K.; Kwon, J.; Li, T.K.; Nurnberger, J.I.Jr.; O'Connor, S.J.; Reich, T.; Rice, J.; Schuckit, M.A.; Porjesz, B.; Foroud, T.; Begleiter, H. Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Hum. Genet. 2004, 74, 705-714.
164. Covault, J.; Gelernter, J.; Hesselbrock, V.; Nellissery, M.; Kranzler, H.R. Allelic and haplotypic association of GABRA2 with alcohol dependence. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2004, 129, 104-109.
165. Enoch, M.A.; Schwartz, L.; Albaugh, B.; Virkkunen, M.; Goldman, D. Dimensional anxiety mediates linkage of GABRA2 haplotypes with alcoholism. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2006, 141, 599-607.
166. Fiorelli, R.; Rudolph, U.; Straub, C.J.; Feldon, J.; Yee, B.K. Affective and cognitive effects of global deletion of alpha3-containing gamma-aminobutyric acid-A receptors. Behav. Pharmacol., 2008, 19, 582-596.
167. Massat, I.; Souery, D.; Del Favero, J.; Oruc, L.; Noethen, M.M.; Blackwood, D.; Thomson, M.; Muir, W.; Papadimitriou, G.N.; Dikeos, D.G.; Kaneva, R.; Serretti, A.; Lilli, R.; Smeraldi, E.; Jakovljevic, M.; Folnegovic, V.; Rietschel, M.; Milanova, V.; Valente, F.; Van Broeckhoven, C.; Mendlewicz, J. Excess of allele 1 for alpha3 subunit GABA receptor Gene (GABRA3) in bipolar patients: a multicentric association study. Mol. Psychiatry, 2002, 7, 201-2077.
168. Henkel, V.; Baghai, T.C.; Eser, D.; Zill, P.; Mergl, R.; Zwanzger, P.; Schule, C.; Bottlender, R.; Jager, M.; Rupprecht, R.; Hegerl, U.; Moller, H.J.; Bondy, B. The gamma amino butyric acid (GABA) receptor alpha-3 subunit gene polymorphism in unipolar depressive disorder: a genetic association study. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2004, 126, 82-87.
169. Puertollano, R.; Visedo, G.; Saiz-Ruiz, J.; Llinares, C.; Fernandezpiqueras, J. lack of association between manic-depressive illness and a highly polymorphic marker from GABRA3 gene. Am. J. Med. Genet., 1995, 60, 434-435.
170. Massat, I.; Souery, D.; Del Favero, J.; Oruc, L.; Jakovljevic, M.; Folnegovic, V.; Adolfsson, R.; Kaneva, R.; Papadimitriou, G.; Dikeos, D.; Jazin, E.; Milanova, V.; Van Broeckhoven, C.; Mendlewicz, J. Lack of association between GABRA3 and unipolar affective disorder: a multicentre study. Int. J. Neuropsychopharmacol., 2001, 4, 273-278.
171. Broekman, B.F.; Olff, M.; Boer, F. The genetic background to PTSD. Neurosci. Biobehav. Rev., 2007, 31, 348-362.
172. Sen, S.; Villafuerte, S.; Nesse, R.; Stoltenberg, S.F.; Hopcian, J.; Gleiberman, L.; Weder, A.; Burmeister, M. Serotonin transporter and GABAA alpha 6 receptor variants are associated with neuroticism. Biol. Psychiatry 2004, 55, 244-249.
173. Uhart, M.; McCaul, M.E.; Oswald, L.M.; Choi, L.; Wand, G.S. GABRA6 gene polymorphism and an attenuated stress response. Mol. Psychiatry, 2004, 9, 998-1006.
174. Pham, X.; Sun, C.; Chen, X.; van den Oord, E.J.; Neale, M.C.; Kendler, K.S.; Hettema, J.M. Association study between GABA receptor genes and anxiety spectrum disorders. Depress. Anxiety, 2009, 26, 998-1003.
175. Atack, J.R. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin. Investig. Drugs, 2005, 14, 601-618.
176. Franco, R. Neurotransmitter receptor heteromers in neurodegenerative diseases and neural plasticity. J. Neural. Transm., 2009, 116, 983-987.
177. Balasubramanian, S.; Teissére, J.A.; Raju, D.V.; Hall, R.A. Heterooligomerization between GABAA and GABAB receptors regulates GABAB receptor trafficking. J. Biol. Chem., 2004, 279, 18840-18850.
178. Da Settimo, F.; Taliani, S.; Trincavelli, M.L.; Montali, M.; Martini, C. GABA A/Bz receptor subtypes as targets for selective drugs. Curr. Med. Chem., 2007, 14, 2680-2701.
179. Olsen, R.W.; Sieghart, W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev., 2008, 60, 243-260.
180. Lippa, A.; Czobor, P.; Stark, J.; Beer, B.; Kostakis, E.; Gravielle, M.; Bandyopadhyay, S.; Russek, S.J.; Gibbs, T.T.; Farb, D.H.; Skolnick, P. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc. Natl. Acad. Sci. USA, 2005, 102, 7380-7385.
181. Knabl, J.; Witschi, R.; Hösl, K.; Reinold, H.; Zeilhofer, U.B.; Ahmadi, S.; Brockhaus, J.; Sergejeva, M.; Hess, A.; Brune, K.; Fritschy, J.M.; Rudolph, U.; Möhler, H.; Zeilhofer, H.U. Reversal of pathological pain thug specific spinal GABAA receptor subtypes. Nature, 2008, 451, 330-334.
182. Knabl, J.; Zeilhofer, U.B.; Crestani, F.; Rudolph, U.; Zeilhofer, H.U. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain, 2009, 141, 233-238.
183. Griebel, G.; Perrault, G.; Simiand, J.; Cohen, C.; Granger, P.; Depoortere, H.; Francon, D.; Avenet, P.; Schoemaker, H.; Evanno, Y.; Sevrin, M.; George, P.; Scatton, B. SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug. Rev., 2003, 9, 3-20.
184. Dias, R.; Sheppard, W.F.; Fradley, R.L.; Garrett, E.M.; Stanley, J.L.; Tye, S.J.; Goodacre, S.; Lincoln, R.J.; Cook, S.M.; Conley, R.; Hallett, D.; Humphries, A.C.; Thompson, S.A.; Wafford, K.A.; Street, L.J.; Castro, J.L.; Whiting, P.J.; Rosahl, T.W.; Atack, J.R.; McKernan, R.M.; Dawson, G.R. Reynolds, D.S. Evidence for a significant role of alpha3-containing GABAA receptors in mediating the anxiolytic effects of Q8 benzodiazepines. J. Neurosci., 2005, 25, 10682-10688
185. Langen, B.; Egerland, U.; Bernoster, K.; Dost, R.; Unverferth, K.; Rundfeldt, C. Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. J. Pharmacol. Exp. Ther., 2005, 314, 717-724.